Douglas Holtzman - 03 Jul 2023 Form 4 Insider Report for Icosavax, Inc.

Role
Chief Scientific Officer
Signature
/s/ Elizabeth Bekiroglu, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
03 Jul 2023
Net transactions value
-$127,733
Form type
4
Filing time
03 Jul 2023, 19:43:15 UTC
Previous filing
05 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICVX Common Stock Options Exercise $17,010 +16,356 +5.6% $1.04* 306,410 03 Jul 2023 Direct
transaction ICVX Common Stock Sale $124,660 -14,261 -4.7% $8.74 292,149 03 Jul 2023 Direct F1, F2
transaction ICVX Common Stock Sale $20,083 -2,095 -0.72% $9.59 290,054 03 Jul 2023 Direct F1, F3
holding ICVX Common Stock 2,792 03 Jul 2023 By Stanley Holtzman( F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICVX Stock Option (Right to Buy) Options Exercise $0 -16,356 -36% $0.000000 28,621 03 Jul 2023 Common Stock 20,443 $1.04 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported herein were made pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on December 2, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.38 to $9.28. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.38 to $9.88. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 Douglas Holtzman, Ph.D. holds power-of-attorney (POA) over the shares owned by Stanley Holtzman. As POA, Dr. Holtzman holds voting and dispositive control over such shares. Dr. Holtzman disclaims beneficial ownership of the shares over which he has POA except to the extent of any pecuniary interest therein.
F5 25% of the shares subject to the option vested on 1/14/2022, and 1/48th of the shares subject to the option vest monthly thereafter.